CHINA BIOPHARMACEUTICALS SUCCESSFULLY COMPLETES ALL CLINICAL TRIALS FOR NAFAMOSTATE MESILATE

China Biopharmaceuticals Holdings, Inc., a leading Chinese pharmaceutical company focused on the development, manufacturing and distribution of innovative drugs in China, announced that it has completed all required clinical trials for one of its new drugs, Nafamostate Mesilate and is waiting for final manufacturing and marketing approval from the State Food and Drug Administration of China (SFDA). The trials were conducted in ten hospitals throughout China. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=4810720)